Multi-Functional Monoamine Oxidase and Cholinesterase Inhibitors for the Treatment of Alzheimer’s Disease

Effect of chlorogenic acid plus donepezil on critical neurocortical enzyme activities, inflammatory markers, and synaptophysin immunoreactivity in scopolamine‐assaulted rats, supported by multiple ligand simultaneous docking

“…Its use, however, has a few limitations such as its selectivity in action; DON selectively inhibits AChE activity and thus a very weak inhibitor of BChE (Mukherjee et al, 2007). On the contrary, it has been reported that as the pathology of AD progresses AChE activities decreases while that of BChE increases in the brain temporal cortex and hippocampus; with both cholinesterases capable of hydrolyzing acetylcholine, it, therefore, suggests that BChE is the primary cholinesterase in action at advanced stages of AD (Alipour et al, 2012;Denya et al, 2019). In agreement with the aforementioned, this current study also observed that scopolamine (SCOP)-administered rats treated with DON ameliorated the significantly elevated AChE activity in the neocortex but their lack of significant difference was observed between the BChE activities in both rats administered SCOP alone and SCOP plus DON.…”

“…It functions to selectively inhibit acetylcholinesterase (AChE) activity, an enzyme that hydrolyses acetylcholine; an elevated AChE leads to rapid breakdown of acetylcholine, which leads to loss of cholinergic neuronal function in AD. However, butyrylcholinesterase (BChE) which is the other type of cholinesterase also hydrolysis acetylcholine and has been reported to predominate in advanced stages of AD (Alipour et al, 2012; Denya et al, 2019). Donepezil has, however, a weak effect on BChE (Mukherjee et al, 2007).…”